Comparison of the efficacy of different mTOR inhibitors for the treatment of prostate cancer

被引：0
|
作者：
D'Abronzo, Leandro Salati
Beggs, Ryan
Bose, Swagata
Ghosh, Paramita
机构：
来源：
CLINICAL CANCER RESEARCH | 2012年 / 18卷 / 10期
关键词：
D O I：
10.1158/1078-0432.MECHRES-A52
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A52
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer
    Rose, C
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (04): : S9 - S16
  • [32] mTor Inhibitors for the Treatment of Endometriosis
    Barra, Fabio
    Ferrero, Simone
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2018, 78 (03) : 283 - 284
  • [33] mTOR inhibitors in cancer therapy
    Zaytseva, Yekaterina Y.
    Valentino, Joseph D.
    Gulhati, Pat
    Evers, B. Mark
    CANCER LETTERS, 2012, 319 (01) : 1 - 7
  • [34] Inhibitors of mTOR in aging and cancer
    Zhavoronkov, Alexander
    ONCOTARGET, 2015, 6 (42): : 45010 - 45011
  • [35] Efficacy of audiotaping the prostate cancer treatment consultation
    Pinnock, CB
    Stapleton, AMF
    Taylor, L
    Boxhall, S
    Dougherty, M
    PSYCHO-ONCOLOGY, 2003, 12 (04) : S154 - S154
  • [36] mTOR pathway components dictate cell response to Src inhibitors in prostate cancer cells
    Dai, Yao
    Siemann, Dietmar W.
    CANCER RESEARCH, 2019, 79 (13)
  • [37] Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells
    Grünwald, V
    DeGraffenried, L
    Russel, D
    Friedrichs, WE
    Ray, RB
    Hidalgo, M
    CANCER RESEARCH, 2002, 62 (21) : 6141 - 6145
  • [38] mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy
    Baldo, Paolo
    Cecco, Sara
    Giacomin, Elisa
    Lazzarini, Renzo
    Rose, Barbara
    Marastoni, Stefano
    CURRENT CANCER DRUG TARGETS, 2008, 8 (08) : 647 - 665
  • [39] mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy
    Gomez-Pinillos, Alejandro
    Ferrari, Anna C.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2012, 26 (03) : 483 - +
  • [40] Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer
    Garcia, Christine A.
    Wu, Shenhong
    CANCER INVESTIGATION, 2016, 34 (10) : 521 - 530
12345